Hereditary forms of amyotrophic lateral sclerosis (ALS) may only account for 10 percent of all ALS cases, but the insights that researchers gain from studying this small population may be the key to unlocking new treatments for this devastating disease.
That’s the hope of Katharine Nicholson, MD, a physician-investigator at the Neurological Clinical and Research Institute (NRCI) at Massachusetts General Hospital. Dr. Nicholson has launched a project called the DIALS Network (Dominant Inherited ALS Network) — a multicenter study based at Mass General and Washington University that tracks the first-degree relatives of individuals who have a familial form of ALS but do not show symptoms yet.
The goal is to identify the earliest molecular and clinical signs of the disease, which could help in developing new strategies to prevent or lessen its impact.
Searching for Biological and Diagnostic Clues
Dr. Nicholson explains that ALS is considered by many neurologists to be a diagnosis of exclusion, meaning that it can only be confirmed after all other possibilities have been ruled out.
“In general, we don’t have good early diagnostic tests,” she says. “It takes about a year from symptom onset to diagnosis, which is sometimes a large portion of their disease duration.”
Identified inherited forms of ALS are autosomal dominant, which means that individuals who carry one copy of the disease-causing gene are going to develop the disease at some point in their lifetime, and it will be seen in most generations of the family as well.
The DIALS teams at Mass General and Washington University have recruited approximately 40 first-degree relatives of individuals with ALS to participate in the study over the past year. The study team provides genetic testing and counseling for participants, and collects blood, spinal fluid and other samples every six months to see if they can identify the first indicators of the disease’s emergence.
“We’re not only looking at the earliest molecular changes, but the earliest clinical changes as well,” Dr. Nicholson explains. “We currently diagnose ALS through a clinical assessment of weakness. This can include weakness in an arm or a leg, or difficulty with breathing, swallowing or speaking.”
By closely following the study participants, Dr. Nicholson and her team may be able to improve clinical assessments to pick up on more subtle indicators of early disease.
Preparing for New ALS Treatments
That information can be used to inform new treatment strategies for familial ALS, which could include gene therapy designed to stop disease progression early on.
“We want to be poised with a population of gene carriers who are asymptomatic, identify the biomarkers (biological indicators) that will help to predict their conversion into disease state, and use the most sensitive clinical measures to assess early disease progression.”
Dr. Nicholson has been overwhelmed by the commitment that families affected by this hereditary form of disease have brought to the research process. “Seeing their proactivity and motivation helps to drive you forward.”
Additional motivation comes from the team at the NCRI, including Merit Cudkowicz, MD, MSc, co-director of the NCRI and chief of Neurology at Mass General, as well as her fellow investigators and study support team. “We couldn’t have a more inspiring team of people working to cure this disease.”
To learn more about how you can support ALS care and research at Mass General, please contact us.
This story first appeared on the website of the Mass General Research Institute.
The Research Institute: Saving Lives Through Science
The Massachusetts General Hospital Research Institute is the largest hospital-based research program in the United States, with a community of more than 8,500 people working across more than 30 institutes, centers and departments.
Our researchers work side-by-side with physicians to pioneer the latest scientific advancements for curing disease and healing patients in Boston, across the United States and around the world.
To learn more about the Research Institute, please visit our website.